Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis. It also offers platform technologies, including Turbo-ZM and Ribosome Modulating Agents; and Eukaryotic Ribosomal Selective Glycosides for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Watertown, Massachusetts.
Metrics to compare | ELOX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELOXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −0.6x | −0.6x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | 0.0x | 1.3x | 2.6x | |
Price / LTM Sales | 0.0x | 1.8x | 3.4x | |
Upside (Analyst Target) | 0.0% | 213.0% | 41.5% | |
Fair Value Upside | Unlock | 21.2% | 4.4% | Unlock |